Atara Biotherapeutics Inc

Latest Atara Biotherapeutics Inc News and Updates

  • uploads///PRTK
    Fund Managers

    Baupost discloses stake in Paratek Pharmaceuticals

    Seth Klarman’s The Baupost Group added a 12.04% stake in Paratek Pharmaceuticals, Inc. (PRTK), according to a 13G filing in December.

    By Samantha Nielson
  • uploads///ATRA focus Therapies
    Company & Industry Overviews

    Inside Atara Biotherapeutics’ Promising Product Pipeline

    Atara’s most advanced T-cell therapy in development is its ATA129, which is under development for the treatment of cancer patients with Epstein Barr virus.

    By Kenneth Smith
  • uploads///FWP stock
    Fund Managers

    Forward Pharma: One of Baupost’s new positions

    Seth Klarman’s The Baupost Group added a 11.72% stake in Forward Pharma (FWP). A November 13G filing shows the fund owns 5,367,300 Forward Pharma shares.

    By Samantha Nielson
  • uploads///LNG
    Fund Managers

    Baupost nearly doubles position in Cheniere Energy

    In its 13G filing in January, The Baupost Group upped its stake in Cheniere Energy (LNG), giving it 10.01% stake in LNG and nearly doubling its 3Q14 filing.

    By Samantha Nielson
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.